British pharmaceutical giant GSK has agreed to acquire U.S.-based oncology specialist Nuvalent for $10.6 billion in cash, marking its largest acquisition in years. The deal, priced at $124 per share—a 40% premium over Nuvalent’s last closing price—underscores CEO Luke Miels' strategy to revitalize GSK's cancer drug pipeline ahead of key patent expirations.
Strategic Rationale and Timing
The acquisition comes as GSK braces for the loss of exclusivity on dolutegravir, its flagship HIV therapy, between 2028 and 2030. With cheaper generics expected to erode sales, Miels is turning to oncology—a sector where GSK has been a laggard. Nuvalent’s late-stage assets could begin generating revenue as early as 2027, helping GSK maintain annual sales above £40 billion by 2031.
Key Assets and Pipeline
Nuvalent’s pipeline is centered on two non-small cell lung cancer (NSCLC) drugs awaiting FDA decisions: zidesamtinib for ROS1-positive NSCLC (decision due by Sept. 18) and neladalkib for ALK-positive NSCLC (decision due by Nov. 27). Both target specific genetic drivers of the most common lung cancer form. Miels described the deal as a “multi-product acquisition,” noting that the two drugs could launch this year if approved. The acquisition also includes NVL-330, an early-stage HER2 inhibitor for HER2-altered NSCLC, and multiple preclinical programs.
The deal further strengthens GSK’s platform for Ris-Rez, an antibody-drug conjugate targeting B7-H3, which is being developed as part of a broader lung cancer franchise.
Market Reaction and Financial Details
Investor sentiment was mixed. Nuvalent shares surged 38.9% in premarket trading to $122.89, while GSK’s London-listed shares fell 1.4% in afternoon trade. The deal is expected to be accretive to GSK’s sales and core operating profit by 2027, but will dilute core earnings per share by low-single digits from 2026 through 2028 if it closes in the third quarter. GSK plans to fund the acquisition with a mix of debt and cash, and does not expect a credit rating impact. The company reaffirmed its 2026 guidance and dividend policy.
Competitive Landscape
Oncology accounted for only about 6% of GSK’s 2025 sales, compared to 44% for rival AstraZeneca, which dominates the lung cancer market. GSK faces competition from Roche, Pfizer, and others. The deal is seen as a bold move to close that gap, though it surprised many analysts given GSK’s typical focus on smaller deals in the $2 billion to $4 billion range.
Execution Risks and Regulatory Hurdles
The deal’s success hinges on FDA approvals and regulatory clearances. GSK will launch a tender offer within 10 business days, requiring over half of Nuvalent’s Class A shares to be tendered. The transaction is subject to Hart-Scott-Rodino antitrust review and includes a Dec. 9 outside date. A breakup fee of $350.475 million applies under certain conditions. Nuvalent’s SEC filing also warns that the FDA could miss its decision deadlines or reject the drugs outright.
Broader Context
This acquisition continues GSK’s rebuilding of its oncology presence after selling its cancer division to Novartis in 2015. Since then, GSK has acquired Tesaro, Sierra Oncology, and IDRx, and signed multiple licensing deals. The Nuvalent purchase represents a significant acceleration of that strategy, but the final outcome will depend on regulatory decisions, clinical trial results, and successful integration.
